SWSuchita Waghmare

Suchita Waghmare

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Suchita Waghmare has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sustainable and stability-indicating RP-HPLC method for Tofacitinib: an integrated white analytical chemistry and A-QbD approach

    by Suchita Waghmare, Ujban Hussain, Rohini Palekar, Pratiksha Bramhe, Nilesh Rarokar, Pramod Khedekar


  • Open Access

    QbD-optimized HA–Pluronic nanomicelles for the targeted repurposing of tofacitinib in breast cancer

    by Suchita Waghmare, Rohini Palekar, Pratiksha Bramhe, Nilesh Rarokar, Pramod Khedekar

    Tofacitinib, a Janus kinase (JAK) inhibitor clinically approved for rheumatoid arthritis, holds significant potential for repurposing in breast cancer therapy due to its ability to suppress the oncogenic STAT3 signaling pathway; however, its therapeutic application is hindered by poor aqueous solubility, rapid systemic clearance, and non-specific distribution. To address these limitations, this study aimed to develop hyaluronic acid (HA)-decorated Pluronic F127 (PF127) micelles to enhance the solubility, bioavailability, and targeted delivery of Tofacitinib to CD44-overexpressing breast cancer cells. A Quality by Design (QbD) approach utilizing a Box–Behnken design (BBD) was employed to systematically optimize critical process parameters—drug-to-polymer ratio, polymer concentration, and stirring temperature—to minimize particle size and polydispersity index (PDI) while maximizing entrapment efficiency. The optimized micelles exhibited a uniform particle size of 159.2 ± 3.8 nm, a narrow PDI of 0.221, a high entrapment efficiency of 91.14%, and a negative zeta potential of −24.6 mV, ensuring colloidal stability. In vitro evaluation demonstrated a sustained, diffusion-controlled drug release profile and significantly enhanced cytotoxicity against MCF-7 breast cancer cells (IC50 14.2 µg mL−1) compared to the free drug (IC50 46.8 µg mL−1), attributed to CD44-mediated cellular uptake. Furthermore, in vivo pharmacokinetic analysis in Wistar rats revealed a 4.3-fold increase in oral bioavailability and a prolonged elimination half-life compared to free Tofacitinib, while histopathological studies confirmed the formulation's biocompatibility and safety in major organs. These findings collectively support the viability of the QbD-optimized HA–PF127 micellar system as a promising nanocarrier platform for the effective oral repurposing of Tofacitinib in breast cancer treatment.


  • Open Access

    DEVELOPMENT AND VALIDATION OF UV-SPECTROPHOTOMETRIC AND RP-HPLC METHODS FOR CURCUMIN-TOFACITINIB NANOCARRIERS: A NOVEL PLATFORM FOR ENHANCED BREAST CANCER THERAPY

    by Suchita Waghmare, Ujban Md Hussain, Nilesh Rarokar, Pramod Khedekar

    Objective: The objective of this study is to develop and validate analytical techniques for the accurate quantification, stability assessment, and quality control of curcumin-tofacitinib-loaded nanocarriers (CS-TF-NCs). Methods: A new RP-HPLC (Reverse Phase-High Performance Liquid Chromatography) and UV-spectrophotometric method was developed and validated to quantify CS (Curcumin), TF (Tofacitinib), and CS-TF-NCs (Curcumin-Tofacitinib-Nanocarriers). UV-spectrophotometry detected λmax values of 426 nm (CS) and 286 nm (TF), and shifts to 287 nm and 421 nm for nanocarrier-loaded samples, with excellent linearity (R² = 0.9994) in the range of 5–25 μg/ml. RP-HPLC analysis was found to be very sensitive with low LOD (Limit of Detection) (LOD = 0.045 μg/ml) and LOQ (Limit of Quantification) (LOQ = 0.07 μg/ml). Recovery levels were between 97% and 99%, and retention times were 2.212 and 4.285 min for CS and TF, respectively. Results: CS and TF revealed λ max values of 426 nm and 286 nm by UV-spectrophotometry, with high correlation coefficients of R² = 0.9962 and 0.998. For CS-TF-NCs, the values were determined at 287 nm and 421 nm with a high R² = 0.9994 that validates linearity for the entire range of concentration of 5–25 μg/ml. Validation through RP-HPLC has exhibited good sensitivity, LOD being 0.045 μg/ml, and high precision (%RSD<1.5%). The nanocarriers were characterized by good solubility and sustained release profiles, giving recovery and retention times of 97–99% with 2.212 and 4.285 min for CS and TF, respectively. Conclusion: This work established CS-TF-NCs as a platform with the potential to deliver targeted, effective breast cancer therapy.


  • Advancements in Nanoparticle-Based Targeted Drug Delivery Systems for Breast Cancer

    by Roshni Kunte, Prafulla Sabale, Suchita Waghmare, Manasi Nikam Jiwankar, Vidya Sabale

    Cancer is a leading cause of death and life-threatening disease globally. It is connected to persistent tissue damage and unregulated cellular proliferation. In females, breast cancer plays a crucial role in death rates. Chemotherapy, alongside surgery, radiation, and hormone therapy, is a first-line treatment, but its non-specific action harms both cancerous and healthy cells, causing severe side effects. The treatment options for breast cancer are based on the disease stage, which spans from stages 0 to IV. To mitigate this issue, novel strategies focusing on specific targets have been introduced in recent times. Advanced nanocarriers are focused on tumor-specific drug delivery using active targeting based on ligand-receptor identification, this approach has the potential to demonstrate enhanced efficacy compared to passive targeting strategies in the context of therapy for human breast cancer. Surface alteration can assist overcome this issue. This overview focuses on modified nano-sized carriers, including liposomes, micelles, polymeric nanocarriers, carbon dots, and gold nanoparticles. It has been studied to improve therapeutics efficacy, bioavailability, and pharmacokinetics features via mechanisms. The primary aim is no longer confined to merely enveloping cancer medications in novel formulations for diverse delivery pathways; instead, the emphasis lies on precise cancer targeting. This review focuses on the stages of breast cancer, obstacles, types of breast cancer therapies, techniques, and various nanocarriers using ligand-mediated drug delivery systems and their mechanisms.


  • Solid Lipid Nanoparticles as an Innovative Lipidic Drug Delivery System

    by Suchita Waghmare, Rohini Palekar, Lata Potey, Pramod Khedekar, Prafulla Sabale, Vidya Sabale

    In order to overcome some of the drawbacks of traditional formulations, increasing emphasis has recently been paid to lipid-based drug delivery systems. Solid lipid nanoparticles (SLNs) are promising delivery methods, and they hold promise because of their simplicity in production, capacity to scale up, biocompatibility, and biodegradability of formulation components. Other benefits could be connected to a particular route of administration or the makeup of the ingredients being placed into these delivery systems. This article aims to review the significance of solid lipid nanocarriers, their benefits and drawbacks, as well as their types, compositions, methods of preparation, mechanisms of drug release, characterization, routes of administration, and applications in a variety of delivery systems with a focus on their efficacy.